The Use of Milrinone Versus Conventional Treatment for the Management of Life-Threatening Bronchial Asthma
SOBHY, AMR;
Abstract
Background and Aims:
In our study, we investigated the effectiveness of intravenous milrinone in life-threatening bronchial asthma as compared to conventional
treatment.
Methods:
Fifty patients aged 18-50 years, presenting with life-threatening asthma were enrolled in a Randomised Controlled Trial (RCT). They were
randomly allocated into Group C (25 patients): who received the standard pharmacotherapy and placebo, and Group M (25 patients): who in
addition to the standard therapy, received 25 μg milrinone as an initial slow IV bolus diluted in 10 ml of normal saline. The following data were
recorded: PEFR (Peak Expiratory Flow Rate) expressed as a percentage of the patient’s previous value, Respiratory Rate (RR), MABP (Mean
Arterial Blood Pressure), arterial blood gases, and the number of patients requiring mechanical ventilation. Differences between groups were tested
using Analysis of Variance (ANOVA) for quantitative variables with post hoc using the Least Significant Difference (LSD) test, and Chi square
test for categorical variables.
Results:
Group M showed marked improvement in PEFR that was highly significant (P < 0.001) 10 min after injection and significant after one hour from
the start of treatment in comparison to Group C. There was also an improvement in RR and PO2 that was significant in group M. Milrinone was
associated with a reduction in MABP only after 10 min from injection, and showed a statistically significant decrease in the number of patients
requiring mechanical ventilator support (P ˂ 0.05).
Conclusion:
Milronine is a promising agent as a rescue drug in the treatment of life-threatening bronchial asthma.
In our study, we investigated the effectiveness of intravenous milrinone in life-threatening bronchial asthma as compared to conventional
treatment.
Methods:
Fifty patients aged 18-50 years, presenting with life-threatening asthma were enrolled in a Randomised Controlled Trial (RCT). They were
randomly allocated into Group C (25 patients): who received the standard pharmacotherapy and placebo, and Group M (25 patients): who in
addition to the standard therapy, received 25 μg milrinone as an initial slow IV bolus diluted in 10 ml of normal saline. The following data were
recorded: PEFR (Peak Expiratory Flow Rate) expressed as a percentage of the patient’s previous value, Respiratory Rate (RR), MABP (Mean
Arterial Blood Pressure), arterial blood gases, and the number of patients requiring mechanical ventilation. Differences between groups were tested
using Analysis of Variance (ANOVA) for quantitative variables with post hoc using the Least Significant Difference (LSD) test, and Chi square
test for categorical variables.
Results:
Group M showed marked improvement in PEFR that was highly significant (P < 0.001) 10 min after injection and significant after one hour from
the start of treatment in comparison to Group C. There was also an improvement in RR and PO2 that was significant in group M. Milrinone was
associated with a reduction in MABP only after 10 min from injection, and showed a statistically significant decrease in the number of patients
requiring mechanical ventilator support (P ˂ 0.05).
Conclusion:
Milronine is a promising agent as a rescue drug in the treatment of life-threatening bronchial asthma.
Other data
Title | The Use of Milrinone Versus Conventional Treatment for the Management of Life-Threatening Bronchial Asthma | Authors | SOBHY, AMR | Keywords | Milrinone;Bronchial asthma;Randomised controlled trial;Phosphodiesterase 3 inhibitors;Airways;Status asthmatics | Issue Date | 10-Apr-2019 | Journal | The Open Anesthesia Journal | Volume | 13 | Start page | 12 | End page | 17 | DOI | 10.2174/2589645801913010012 |
Attached Files
File | Description | Size | Format | Existing users please Login |
---|---|---|---|---|
asthma.pdf | The Use of Milrinone Versus Conventional Treatment for the Management of Life-Threatening Bronchial Asthma | 242.85 kB | Adobe PDF | Request a copy |
Similar Items from Core Recommender Database
Items in Ain Shams Scholar are protected by copyright, with all rights reserved, unless otherwise indicated.